Feis Equities and Lawrence Feis disclose 5.08% ownership in DMAA (DMAA)
Rhea-AI Filing Summary
Drugs Made In America Acquisition Corp. reports that Feis Equities LLC and Lawrence M. Feis beneficially own 1,232,775 Ordinary shares, representing 5.08% of the class. The filing cites 24,276,913 Ordinary shares outstanding as of May 14, 2026 from the issuer's 10-Q.
The Schedule 13G shows sole voting and dispositive power over the 1,232,775 shares for both reporting persons and is signed by Lawrence M. Feis.
Positive
- None.
Negative
- None.
Insights
Feis Equities LLC reports a 5.08% passive stake in DMAA.
The filing lists 1,232,775 shares beneficially owned and cites 24,276,913 shares outstanding as of May 14, 2026 from the issuer's 10-Q; the percentage is calculated from that outstanding figure. The reporting persons state sole voting and dispositive power over the disclosed shares.
Because this is a Schedule 13G disclosure of beneficial ownership, the holding is presented as passive under the filing's terms; subsequent filings could change the ownership picture.
Ownership is attributed to both an LLC and an individual via a joint filing agreement.
The cover rows identify Feis Equities LLC and Lawrence M. Feis with identical share counts and percentages; Exhibit A is a Joint Filing Agreement. The signature block shows the Managing Member and the individual signed on 06/25/2026.
This filing documents reported beneficial ownership and control attributes; any change in voting or dispositive power would require an updated filing.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned regulatory
Sole Dispositive Power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.